Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.38 |
| ▸ | PRPS1 | P60891 | 2/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | CPT1A | P50416 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 5/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289050 | 1.00 | KDM4C (0.40) | KDM4CPIN1KMOGRIN2BHCAR1 | |
| SCHEMBL4285431 | 0.88 | HCAR1 (0.38) | GRIN2BHCAR1TGFBR1 | |
| SCHEMBL4287476 | 0.87 | F2R (0.38) | KDM4CGRIN2BHCAR1PRPS1TGFBR1 | |
| SCHEMBL4281165 | 0.87 | HCAR1 (0.43) | HCAR1 | |
| SCHEMBL4281946 | 0.86 | TGFBR1 (0.46) | KDM4CHCAR1TGFBR1 | |
| SCHEMBL4788338 | 0.86 | HCAR1 (0.44) | HCAR1 | |
| SCHEMBL4788332 | 0.86 | HCAR1 (0.44) | HCAR1 | |
| SCHEMBL4788333 | 0.86 | HCAR1 (0.44) | HCAR1 | |
| SCHEMBL4291087 | 0.84 | TRPM8 (0.44) | — | |
| SCHEMBL4291358 | 0.80 | HCAR1 (0.38) | GRIN2BHCAR1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KDM4C 506/4885PIN1 778/4885KMO 1204/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KDM4C 506/4885PIN1 778/4885KMO 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.